{"nct_id": "NCT06486441", "age": "Adults", "cancer_center_accrual_goal_upper": 0, "data_table4": "Interventional", "drug_list": {"drug": [{"drug_name": "Drug: Sacituzumab govitecan-hziy"}, {"drug_name": "Drug: Paclitaxel"}, {"drug_name": "Drug: Doxorubicin"}]}, "long_title": "A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy", "management_group_list": {"management_group": [{"is_primary": "Y", "management_group_name": "Group1"}]}, "oncology_group_list": {"oncology_group": [{"group_name": "Group1", "is_primary": "N"}]}, "phase": "PHASE3", "principal_investigator": "Gilead Study Director", "principal_investigator_institution": "Gilead Sciences", "program_area_list": {"program_area": [{"is_primary": "Y", "program_area_name": "Program1"}]}, "protocol_id": 0, "protocol_no": "", "protocol_target_accrual": 520, "protocol_type": "INTERVENTIONAL", "prior_treatment_requirements": ["Key Inclusion Criteria:", "* Documented evidence of recurrent/persistent endometrial cancer (endometrial carcinoma or carcinosarcoma).", "* Up to 3 prior lines of systemic therapy for endometrial cancer, including systemic platinum-based chemotherapy and anti-PD-1/PD-L1 therapy, either in combination or separately.", "* Eligible for treatment with either doxorubicin or paclitaxel as determined by the investigator.", "* Radiologically evaluable disease (either measurable or nonmeasurable) by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1.", "* Eastern Cooperative Oncology Group performance status score of 0 or 1.", "* Adequate organ function", "Exclude - Key Exclusion Criteria:", "Exclude - * Uterine leiomyosarcoma and endometrial stromal sarcomas are excluded.", "Exclude - * Participants who are candidates for curative-intent therapy at the time of study enrollment.", "Exclude - * Participants eligible for rechallenge with platinum-based chemotherapy as determined by the investigator.", "Exclude - * Received any prior treatment with a Trop-2-directed antibody-drug conjugate (ADC).", "Exclude - * Have an active second malignancy.", "Exclude - * Have an active serious infection requiring systemic antimicrobial therapy.", "Exclude - * Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal perforation within 6 months prior to randomization.", "Exclude - * Have a positive serum pregnancy test or are breastfeeding for participants who are assigned female at birth.", "Exclude - Note: Other protocol defined Inclusion/Exclusion criteria may apply."], "short_title": "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)", "site_list": {"site": []}, "sponsor_list": {"sponsor": [{"is_principal_sponsor": "Y", "sponsor_name": "Gilead Sciences", "sponsor_protocol_no": "", "sponsor_roles": "sponsor"}]}, "staff_list": {"protocol_staff": []}, "status": "open to accrual", "summary": "The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC).\n\nThe primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).", "treatment_list": {"step": [{"arm": [{"arm_code": "Sacituzumab Govitecan (SG)", "arm_internal_id": 0, "arm_description": "Participants will receive SG at a dose of 10 mg/kg on Days 1 and 8 of a 21-day cycle.", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Sacituzumab govitecan-hziy", "level_internal_id": 0, "level_suspended": "N"}]}, {"arm_code": "Treatment of Physician's Choice (TPC)", "arm_internal_id": 1, "arm_description": "Participants will receive one of the following TPC, regimens determined prior to randomization.\n\n* Doxorubicin 60 mg/m\\^2 IV on Day 1 of a 21-day cycle\n* Paclitaxel 80 mg/m\\^2 IV on Days 1, 8, and 15 of a 28-day cycle", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Doxorubicin", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Paclitaxel", "level_internal_id": 1, "level_suspended": "N"}]}], "match": [{"and": [{"clinical": {"oncotree_primary_diagnosis": "", "disease_status": ["", ""]}}, {"genomic": {"hugo_symbol": "", "variant_category": ""}}]}]}]}}